IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2(V617F)-positive myeloproliferative neoplasms

The recurrent V617F mutation in JAK2 (JAK2(V617F)) has emerged as the primary contributor to the pathogenesis of myeloproliferative neoplasms (MPN). However, the lack of complete response in most patients treated with the JAK1/2 inhibitor, ruxolitinib, indicates the need for identifying pathways tha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: de Melo Campos, Paula, Machado-Neto, João A., Eide, Christopher A., Savage, Samantha L., Scopim-Ribeiro, Renata, da Silva Souza Duarte, Adriana, Favaro, Patricia, Lorand-Metze, Irene, Costa, Fernando F., Tognon, Cristina E., Druker, Brian J., Saad, Sara T. Olalla, Traina, Fabiola
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872760/
https://ncbi.nlm.nih.gov/pubmed/26755644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6851
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados